Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
SHEZF · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $1,423 | $1,394 | $1,212 | $1,232 |
| % Growth | 2.1% | 15.1% | -1.6% | – |
| Cost of Goods Sold | $926 | $1,013 | $807 | $869 |
| Gross Profit | $497 | $381 | $405 | $363 |
| % Margin | 34.9% | 27.3% | 33.4% | 29.5% |
| R&D Expenses | $63 | $40 | $82 | $49 |
| G&A Expenses | -$41 | $98 | -$164 | $235 |
| SG&A Expenses | $14 | $191 | -$135 | $361 |
| Sales & Mktg Exp. | $55 | $93 | $28 | $127 |
| Other Operating Expenses | $115 | -$29 | $621 | -$168 |
| Operating Expenses | $192 | $202 | $567 | $243 |
| Operating Income | $305 | $179 | -$162 | $120 |
| % Margin | 21.5% | 12.8% | -13.4% | 9.8% |
| Other Income/Exp. Net | $0 | -$1 | $1 | -$1 |
| Pre-Tax Income | $305 | $178 | -$161 | $120 |
| Tax Expense | $40 | $22 | -$7 | $3 |
| Net Income | $265 | $157 | -$133 | $116 |
| % Margin | 18.6% | 11.2% | -11% | 9.5% |
| EPS | 0.18 | 0.11 | -0.091 | 0.079 |
| % Growth | 63.6% | 221% | -214.5% | – |
| EPS Diluted | 0.18 | 0.11 | -0.091 | 0.079 |
| Weighted Avg Shares Out | 1,468 | 1,468 | 1,467 | 1,467 |
| Weighted Avg Shares Out Dil | 1,468 | 1,468 | 1,467 | 1,467 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10 | $9 | $11 | $15 |
| Interest Expense | $18 | $22 | $31 | $31 |
| Depreciation & Amortization | $0 | $0 | $0 | $30 |
| EBITDA | $323 | $201 | -$130 | $181 |
| % Margin | 22.7% | 14.4% | -10.8% | 14.7% |